Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
There has been a lot of speculation as to what Dendreon would charge for a course of treatment with sipuleucel-T (Provenge). For 2 years, The “New” Prostate Cancer InfoLink has been telling readers that we expected this price to be not less than $75,000.
Filed under: Management, Treatment | Tagged: price, Provenge, sipuleucel-T | 5 Comments »
IRIS Molecular Diagnostics has submitted an application to the U.S. Food and Drug Administration to market a prostate cancer prognostic test called NADiA® ProsVue™. The company says that this test is “designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.”
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: NADiA, prognosis, ProsVue, radical prostatectomy | Leave a Comment »
On April 13, 2010, Dan Zenka learned he had prostate cancer. … But why would we call this out as being of any special note
Filed under: Living with Prostate Cancer | Comments Off
The US Food and Drug Administration has just announced that sipuleucel-T (Provenge) is approved for the treatment of patients with “asymptomatic or minimally symptomatic prostate cancer that has spread to other parts of the body and is resistant to standard hormone treatment.” Click here to see a copy of the FDA’s media release.
Filed under: Management, Treatment | Tagged: Provenge, sipuleucel-T | 1 Comment »
Docetaxel + prednisone is the current standard treatment for men with castration-resistant prostate cancer (CRPC). However, the survival benefit of this form of treatment is small compared to older forms of therapy.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant prostate cancer, combination, CRPC, docetaxel, ketoconazole | Leave a Comment »
There has been a flurry of media stories as the “drop dead date” for a decision about approval of sipuleucel-T (Provenge) gets closer and closer.
Filed under: Drugs in development, Management, Treatment | Tagged: media, Provenge, sipuleucel-T | 4 Comments »
Evidence continues to accumulate that serum levels of C-reactive protein (CRP) may have value as a prognostic marker for survival in men with very early and very late-stage forms of prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: C-reactive protein, castration-resistant prostate cancer, CRP, CRPC, Diagnosis, localized, prognosis, risk | Leave a Comment »
In February this year we noticed the abstract of a paper about “The use of dynamic contrast-enhanced (DCE) imaging for delineation of prostate tumors” and the use of “probability mapping” to assist in the treatment planning process.
Filed under: Management, Treatment | Tagged: DCE, DCE-CT, dynamic contrast-enhanced imaging, probability mapping, radiation therapy | Leave a Comment »
Many patients with no specific evidence of metastatic disease now receive primary androgen deprivation therapy (PADT) much earlier than was the case before the availability of the PSA test. This includes patients who get hormone therapy for a rising PSA after other forms of first-line therapy and patients who receive hormone therapy as their first-line [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, hormone therapy, primary | 4 Comments »
There is significant evidence that serum levels of vitamin D have impact on the overall health of people as they age, and there has been some (largely laboratory-based) evidence of a specific association between vitamin D levels and risk for prostate cancer.
Filed under: Diagnosis, Prevention, Risk | Tagged: risk, vitamin D | Leave a Comment »
TRACON Pharmaceuticals has announced the initiation of a Phase I/II clinical trial of its investigational monoclonal antibody TRC 105 for the treatment of patients with metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: monoclonal antibody, TRC 105 | Leave a Comment »
This is the week that the US FDA is expected to announce approval of the first “cancer vaccine” in the USA — sipuleucel-T (Provenge) for the treatment of hormone-refractory prostate cancer. This is a big deal for all sorts of reasons. There was an interesting article in Saturday’s Seattle Times on cancer vaccines in general [...]
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Comments Off
Reports occur in the media on a regular basis in which journalists talk about their personal experiences in diagnosis and treatment of prostate cancer. These reports can be misleading because,
Filed under: Management, Treatment | Tagged: gold standard, PBRT, proton beam radiation therapy | 3 Comments »
… after you pass away, this is the sort of study that you may be able to watch it be used for (always assuming that there is actually a life after death and that you have the ability to observe what happens to your prior “vessel”).
Filed under: Management, Treatment | Tagged: ablation, focal therapy, laser | 4 Comments »
Results from an international survey of patient perceptions about their prostate cancer treatment were announced yesterday.
Filed under: Living with Prostate Cancer, Management | Tagged: sex, support, Treatment | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site